Mindesta Inc.

Mindesta Inc. CTT Pharmaceuticals Inc. has issued an update from its president to shareholders. The update is as follows: To CTT Shareholders: Let me first take this opportunity to thank you for your continued interest in CTT Pharmaceuticals. Our gains have been a direct result of the continued support of shareholders like you. At this time, I would like to provide you with an update on our activities and a view [...]

The Board of Directors of Mindesta is pleased to announce the appointment of Dr. Stephen Houldsworth to it's advisory board of CTT Pharmaceuticals effective immediately: "I am pleased to be working with CTT in an advisory role as they work to create evidence based medicines within the Cannabis arena using their novel drug delivery systems. At a time when medical Marijuana is seeing greater acceptance into main [...]

The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management products including the use of digital technology. In order to assist in [...]

The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management products including the use of digital technology. In order to assist in [...]

The Board of Directors of Mindesta is pleased to announce the appointment of Graham Wong to Vice President, Marketing of CTT Pharmaceuticals management team. "Part of CTT's strategy is to partner with cannabis producers with domestic legislative advantages. It was important for us to have the ability to properly design, package and market products for potential partners worldwide. To this end Mr. Wong's background in [...]

The Board of Directors of Mindesta Inc. is pleased to announce the appointment of Lucie Lettellier to Chief Financial Officer (CFO) of CTT Pharmaceuticals, effective immediately. Lucie Letellier is a financial professional with specialization in finance and accounting. From 2005 to 2009 Lucie was the CFO of Paramount Gold and Silver Corp. (NYSE/TSX: PZG) having contributed to the development of the company from a [...]

The Board of Directors of Mindesta is pleased to announce the appointment of Steve Abboud to the Advisory Board of CTT Pharmaceuticals, effective immediately. "As part of CTT's overall business strategy, we required a subject matter expert within the medicinal marijuana industry. Steve brings a wealth of knowledge in all facets of medicinal marijuana, therefore his perspective on our goals as well as his wealth of [...]

The Board of Directors of Mindesta today announced the appointment of Gilles Derome and Dr. Dana Allen as Advisory Board members of the firm - CTT Pharmaceuticals, effective immediately. Gilles Derome brings more than twenty-five years of marketing-sales and senior management experience in pharmaceuticals combined with consulting for bio-pharmaceutical companies. Through his pharmaceutical career at Sandoz/Novartis [...]

Mindesta has closed on its acquisition of of CTT Pharmaceuticals, The Company, CTT Pharma and the shareholders of CTT Pharma executed a share exchange agreement which provide in part for the Company to acquire all the issued and outstanding shares of common stock of CTT Pharma in exchange for 149,183,285 shares of the Company's common stock. With the acquisition of CTT Pharma, the Company has 184,368,022 shares of [...]

Mindesta announces that it has completed a non brokered private placement consisting of the sale of 15,783,332 units at a price of US$0.015 per unit for total proceeds of US$236,750. Each unit consists of one common share and one half of a share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $0.0175 until December 31, 2016. In addition, Mindesta has reached [...]